Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement (Mobilise-D) brings together clinicians, scientists, prominent academic centres, businesses, and the world’s largest pharmaceutical and medical industries to revolutionise assessment of mobility loss using digital technology, leading to a game changer for clinical trials and clinical management of mobility.

Imagine being able to monitor your mobility and health with the help of small sensors worn on your body, coupled with personalized algorithms – and to do this on a daily basis, without the need to see your physician or go to a clinic.

Impossible?
The overarching objectives of Mobilise-D are threefold:
  (1) deliver a valid solution for real-world digital mobility assessment;
  (2) validate digital mobility outcomes to predict clinical endpoints in Chronic Obstructive Pulmonary Disease, Parkinson’s Disease, Multiple Sclerosis, Proximal Femoral Fracture Recovery, and Congestive Heart Failure;
  (3) obtain key regulatory and health stakeholder approval for digital mobility assessment.
We need innovative interventions – but we lack reliable solutions to predict, detect, and measure mobility loss. Digital technology, including body worn sensors, has the potential to transform how we assess mobility.

Our results will directly facilitate drug development and establish the roadmap for clinical implementation of new, complementary tools to identify, stratify, and monitor disability, paving the way towards better personalised healthcare.
Project launch April 11th Newcastle, United Kingdom
Consortium Partners